Tool
Supplement comparison tool
Pick up to 4 knowledge base entries and compare their dosage, price, evidence strength and ratings side by side — you can save or share a link to your selection.
Add to comparison (2/4)
| Category | Biohacking | Biohacking |
| Evidence strength | Early-stage evidence | Moderate evidence |
| Evidence Score | 2/5 | 3/5 |
| User rating | 4.3 (58) | 4.4 (79) |
| Typical dose | Exclusively within approved clinical trials: a single 25 mg dose (the "therapeutic" dose in the COMPASS Pathways trial) or a two-session protocol of 20–30 mg in the Johns Hopkins trial, each time under the direct supervision of two trained therapists in a clinical office. | — |
| Form | Synthetic, standardized psilocybin in capsule form — not natural mushrooms with variable, unpredictable active-substance content. | — |
| Average price | — | — |
| Monthly cost | — | — |
| Time to effects | Subjective, acute psychedelic effects appear 20–40 minutes after dosing and last 4–6 hours. The antidepressant effect, if it occurs, tends to be noticeable within days of the session, and in the COMPASS Pathways trial was still partially measured at 12 weeks — though in some patients it faded over time and required consideration of another session or a return to standard treatment. | Not applicable — HRV is a monitoring indicator, not an intervention; changes in the trend become visible after several days to weeks of observation. |
| Who it's for | Exclusively participants in approved clinical trials on treatment-resistant depression, qualified after detailed psychiatric assessment | Athletes wanting to objectively monitor training load and recovery |